| ||Audit Committee||Compensation Committee||Nominating and Corporate Governance Committee||Science and Technology Committee|
|Eugene A. Bauer, M.D. |
|Eugene A. Bauer, M.D.|
Founder & Chief Medical Officer
Dr. Bauer is a co-founder of Dermira, our Chief Medical Officer and a member of our board of directors. Prior to founding Dermira, he served as a member of Peplin’s board of directors, and its President and Chief Medical Officer, until its acquisition by LEO Pharma in 2009. He was also the Chief Executive Officer of Neosil Inc., and a co-founder and member of the board of directors at Connetics. Before initiating his career in industry, Dr. Bauer served as the Dean of the Stanford University Sch...
| || || ||
|David E. Cohen, M.D., M.P.H. |
|David E. Cohen, M.D., M.P.H.|
Professor, Vice Chairman of Clinical Affairs Department of Dermatology at New York University School of Medicine
Dr. Cohen joined Dermira as a director in 2014, after previously serving as a scientific advisor from our inception. He has held a variety of positions at the New York University School of Medicine, including Charles C. and Dorothea E. Harris Professor of Dermatology, Vice Chairman of Clinical Affairs, Chief of Allergy and Contact Dermatitis, and Director of Occupational and Environmental Dermatology. He has served as a lecturer of Environmental Sciences at the Columbia University School of Publ...
|Fred Craves, Ph.D. |
|Fred Craves, Ph.D. |
Investment Partner, Managing Director and Founder, Bay City Capital
Dr. Craves has been a director of Dermira since 2010. He is an investment partner, a Managing Director and a co-founder of Bay City Capital (BCC), and has served as a member of the board of directors and Chairman of the executive committee of BCC since June 1997. Prior to founding BCC, he founded Burrill & Craves, a merchant bank focused on biotechnology and emerging pharmaceutical companies. Dr. Craves served as Executive Vice President of Schering Berlin, Inc., and Chief Executive Officer and ...
|Matthew Fust |
Former Executive Vice President and Chief Financial Officer, Onyx Pharmaceuticals
Mr. Fust has been a director of our company since April 2014. He is a board member and advisor to life sciences companies. Mr. Fust retired as Executive Vice President and Chief Financial Officer at Onyx Pharmaceuticals, Inc., where he served from January 2009 until its acquisition by Amgen in October 2013. Prior to joining Onyx, Mr. Fust was Senior Vice President and Chief Financial Officer at Jazz Pharmaceuticals, Inc., a biopharmaceutical company from May 2003 to December 2008. From May 2002...
|| || |
|Jake Nunn |
Partner, New Enterprise Associates
Mr. Nunn has been a director of Dermira since 2011. He has been a Partner at New Enterprise Associates, Inc. (NEA) since June 2006. Prior to joining NEA, Mr. Nunn served as a Partner and an analyst for the MPM BioEquities Fund, a life sciences fund at MPM Capital, L.P., a private equity firm. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex, Brown & Sons. Mr. Nunn currently also serves on the board of dire...
| || ||
|William Ringo |
Former Senior Advisor, Barclays Healthcare Group and Strategic Advisor to Sofinnova Ventures
Mr. Ringo joined Dermira as a director in 2014. He previously served as a senior advisor to Barclays Healthcare Group and as a strategic advisor to Sofinnova Ventures after retiring from Pfizer in 2010, where he was Senior Vice President of Business Development and Corporate Strategy. Prior to Pfizer, he served as an executive in residence at Warburg Pincus and Sofinnova Ventures, as President and Chief Executive Officer of Abgenix, Inc. and held a number of senior positions in the oncology and ...
|| || |
|Kathleen Sebelius |
Kathleen Sebelius | 21st U.S. Secretary of Health and Human Services
Ms. Sebelius joined Dermira as a director in 2015. Ms. Sebelius was Secretary of Health and Human Services from 2009 to 2014. As Secretary, she presided over 11 operating divisions, including the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) and National Institutes of Health (NIH), and an annual budget approaching $1 trillion. She also oversaw the passage and implementation of the Affordable Care Act, the most significant health reform in half a century.
| || ||
|Thomas G. Wiggans |
|Thomas G. Wiggans|
Founder & Chief Executive Officer
Mr. Wiggans co-founded Dermira in 2010 and is our Chief Executive Officer and Chairman of our board of directors. He brings over 30 years of experience in specialty pharma and 18 years of experience in dermatology. Prior to founding Dermira, Mr. Wiggans served as Chairman of the board of directors and Chief Executive Officer of Peplin, Inc. until Peplin’s acquisition by LEO Pharma A/S in 2009. Previously, he served as Chairman of the board of directors and Chief Executive Officer of Connetics ...
| || || || |